Skip to content
The BCI Briefing

Company profileCore BCI

ABILITY Neurotech

A fully implanted ECoG system that sends raw neural data through the skin by infrared light.

Location
Geneva, Switzerland
Founded
2025
Also known as
ABILITY · Ability Neurotech
Sources last checked
4 Oct 2026

What they are building

Geneva spin-out of the Wyss Center developing a battery-free implant with 128-channel surface arrays and an optical data link, aimed first at restoring communication.

Interface category
Electrocorticography
Signal
Local field potentials, including high-gamma activity
Invasiveness
Invasive
Recording / stimulation
Recording
Device
ABILITY system — Battery-free implant with surface electrode arrays and an infrared optical data link through the skin
Channels
128-channel arrays
Regulatory status
Investigational; intraoperative use reported, chronic study planned
Main use cases
Communicate, Control
Works with
Wyss Center for Bio and Neuroengineering · UMC Utrecht · Graz University of Technology

Where they are clinically

First-in-human

The first use of a device in a small number of people, focused on safety.

Human use so far is intraoperative and brief. The first chronic implant study has ethics approval in the Netherlands and had not begun as of August 2026.

Access today

Experimental human research

Demonstrated in a small number of research participants. Not an established treatment.

Shown in people
Brief recordings during surgery in Germany. The 50 megabit per second optical link and the 128-channel arrays are design figures.
Still an aim
A one-year home-use study in people with ALS at UMC Utrecht, planned for late 2026.
What stands in the way
Chronic performance: how an optical link through skin behaves over months of daily use.

On record here: 0 peer-reviewed papers

This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.

Why this company matters

ABILITY is the most concrete European answer to the question of how to get high-bandwidth data out of a sealed implant: light, not radio, at a reported 50 megabits per second, with no battery inside the head. Its first chronic study is planned at the centre that ran the longest home-use ECoG implant on record. Until that study reports, the performance of the link in daily life is a design claim.

Key milestones

  1. 20 Aug 2026

    Intraoperative study under way in Germany. A one-year home-use study in people with ALS is planned for late 2026 at UMC Utrecht, with TU Graz and CorTec as partners; the company says a Dutch ethics committee has approved the device dossier.

    IEEE Spectrum

  2. 2025

    Spun out of the Wyss Center for Bio and Neuroengineering in Geneva.

    IEEE Spectrum

Leadership

  • Rotem Kopel

    CEO

As publicly stated by the organisation. Not a complete list.

Competitive context

Latest BCI Briefing coverage

Sources

  1. 01

    Ability Neurotech Infrared BCI to Begin Human Trials (opens in a new tab)

    Independent reportingIEEE Spectrum20 Aug 2026Checked against source 4 Oct 2026

    Reports the intraoperative study, the planned Utrecht study, the device specifications and an outside researcher's caution about long-term performance.

  2. 02

    ABILITY Neurotech Receives Approval to Start Clinical Trial (opens in a new tab)

    Company reportedWyss Center for Bio and NeuroengineeringChecked against source 4 Oct 2026

    Announcement by the institute the company was spun out of. The page carries no date.